Shares of Mirna Therapeutics, Inc. (NASDAQ:MIRN) have earned an average recommendation of “Hold” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating. The average 12-month price target among brokerages that have covered the stock in the last year is $1.83.

Separately, Cantor Fitzgerald restated a “hold” rating and issued a $2.00 price target on shares of Mirna Therapeutics in a report on Thursday, April 13th.

An institutional investor recently raised its position in Mirna Therapeutics stock. Vanguard Group Inc. raised its stake in Mirna Therapeutics, Inc. (NASDAQ:MIRN) by 15.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 178,387 shares of the biotechnology company’s stock after buying an additional 23,520 shares during the period. Vanguard Group Inc. owned approximately 0.86% of Mirna Therapeutics worth $391,000 as of its most recent filing with the SEC. 37.34% of the stock is currently owned by institutional investors.

Shares of Mirna Therapeutics (MIRN) traded up 1.9324% during midday trading on Tuesday, hitting $1.5086. 115,500 shares of the stock were exchanged. Mirna Therapeutics has a 12 month low of $1.12 and a 12 month high of $4.82. The firm has a 50 day moving average of $1.73 and a 200-day moving average of $1.94. The stock’s market cap is $31.46 million.

COPYRIGHT VIOLATION WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with's FREE daily email newsletter.